Welcome to our dedicated page for Cadrenal Therape news (Ticker: CVKD), a resource for investors and traders seeking the latest updates and insights on Cadrenal Therape stock.
Cadrenal Therapeutics develops biopharmaceutical therapies for life-threatening immune and thrombotic conditions. News about Cadrenal Therapeutics centers on CAD-1005, its investigational selective 12-lipoxygenase inhibitor for heparin-induced thrombocytopenia, including clinical-study results, FDA communications, pivotal-trial design guidance, and research involving the broader 12-LOX inhibitor platform.
Company updates also cover pipeline assets such as tecarfarin, an oral vitamin K antagonist for chronic anticoagulation settings, and frunexian, a parenteral Factor XIa inhibitor for acute hospital use. Recurring financial news includes quarterly results, cash resources, equity financings, and strategic alternatives tied to the company’s clinical development plans.
Cadrenal Therapeutics (Nasdaq: CVKD) has aligned its clinical portfolio into a Cardiac Acute Critical Care Franchise and launched a structured process to seek out-licensing, portfolio monetization, or co-development partnerships for its late-stage assets CAD-1005, frunexian and tecarfarin.
The franchise is organized into three pillars: Phase 2-ready IV Factor XIa inhibitor frunexian for pre-operative safety in HIT-susceptible CABG patients; Phase 3-ready orphan-focused programs including tecarfarin; and Phase 3-ready IV 12-LOX inhibitor CAD-1005 for post-operative HIT. Recently presented Phase 2 data for CAD-1005 at ISTH 2026 showed an absolute thrombotic event reduction of >25%, with a favorable safety and renal-protective baseline. Cadrenal is also advancing tecarfarin into rare pediatric indications and maintaining development in ESKD and LVADs, while progressing CAD-2000, a preclinical oral 12-LOX inhibitor for chronic cardiorenal inflammatory and thrombotic conditions.
Cadrenal Therapeutics (Nasdaq: CVKD) reported late-breaking Phase 2 data for first-in-class 12-LOX inhibitor CAD-1005 in heparin-induced thrombocytopenia (HIT) at the ISTH 2026 Congress in Paris. In the first randomized, blinded, placebo-controlled HIT trial, CAD-1005 showed an absolute reduction of more than 25% in new or worsening thrombotic events versus placebo (50% vs >75%).
The study, which was not powered for statistical significance, also showed no serious adverse events attributable to CAD-1005, no major bleeding in SRA+ patients, and no deaths. CAD-1005 is described as Phase 3‑ready, targets a life-threatening immune-mediated clotting disorder with an estimated $2 billion peak annual revenue opportunity, and holds FDA Orphan Drug and Fast Track designations as well as EMA Orphan Drug status.
Cadrenal Therapeutics (Nasdaq: CVKD) entered a definitive agreement for a private placement of 960,000 common shares (or pre-funded warrants) plus series C-1 and C-2 warrants for up to 1,920,000 additional shares, at a combined $3.125 per share, raising expected gross proceeds of $3 million.
Total potential gross proceeds, including full cash exercise of all warrants, are about $8.8 million. According to Cadrenal Therapeutics, net proceeds are expected to extend the cash runway into Q1 2027, and, with full warrant exercise, into the second half of 2027 to support partnering for tecarfarin in Kawasaki Disease and CAD-1005 in CSA-AKI and HIT.
Cadrenal Therapeutics (Nasdaq: CVKD) announced that late-breaking Phase 2 data for its first-in-class 12-lipoxygenase inhibitor CAD-1005 for heparin-induced thrombocytopenia (HIT) were selected for a prestigious oral presentation at the ISTH 2026 Congress in Paris.
The Phase-3-ready program targets a HIT market with peak annual revenue potential of $2 billion, according to Cadrenal. The study is described as the first-ever randomized, blinded, placebo-controlled trial in HIT.
Cadrenal Therapeutics (Nasdaq: CVKD) plans to file for FDA Rare Pediatric Disease Designation for tecarfarin in Kawasaki disease patients with coronary artery aneurysms needing chronic anticoagulation.
If designation and approval are achieved, Cadrenal could qualify for a transferable Priority Review Voucher, while also advancing its Phase 3‑ready CAD‑1005 12‑LOX inhibitor portfolio under a dual-track partnering strategy.
Cadrenal Therapeutics (Nasdaq: CVKD) plans a Phase 2a proof-of-concept trial of CAD-1005 to prevent cardiac surgery-associated acute kidney injury (CSA-AKI) in high-risk patients, starting later in 2026.
The trial aims to generate safety, renal injury and 12-LOX pathway data relevant to both CSA-AKI and Cadrenal’s Phase 3-ready HIT program, supporting potential non-dilutive pharma partnerships at BIO 2026.
Cadrenal Therapeutics (Nasdaq: CVKD) will participate in the BIO International Convention 2026 Partnering Event, held June 22–25, 2026 in San Diego. Management plans partnering meetings focused on Phase 3‑ready CAD-1005 for Heparin-Induced Thrombocytopenia (HIT), its broader 12-LOX inhibitor platform, and late-stage oral anticoagulant tecarfarin.
CAD-1005 has completed an End-of-Phase 2 FDA meeting outlining a single pivotal Phase 3 path, following Phase 2 data suggesting reduced thrombotic events in HIT. The 12-LOX platform targets inflammatory and metabolic diseases, while tecarfarin holds FDA Orphan Drug and Fast Track designations for high-risk ESRD/AFib and LVAD-related populations.
Cadrenal Therapeutics (Nasdaq: CVKD) will participate in the virtual Lytham Partners Spring 2026 Investor Conference on May 28, 2026. The company will deliver a webcast presentation and hold one-on-one investor meetings.
The webcast is scheduled for 9:30 a.m. ET and will be available for replay.
Cadrenal Therapeutics (NASDAQ: CVKD) reported Q1 2026 results and FDA End-of-Phase 2 minutes for CAD-1005 in suspected heparin-induced thrombocytopenia (HIT). The company plans a randomized, blinded, placebo-controlled pivotal Phase 3 (~120 patients) to support a projected NDA submission in 2029. Phase 2 showed >25% absolute reduction in thrombotic events when CAD-1005 was added to standard anticoagulation. Q1 operating loss was $2.5M; cash was $2.3M as of March 31, 2026, and a $2.5M financing closed April 1, 2026.
Cadrenal Therapeutics (Nasdaq: CVKD) reported completion of an End-of-Phase 2 meeting with the FDA and received guidance to advance CAD-1005 into a pivotal Phase 3 registration trial for heparin-induced thrombocytopenia (HIT).
The planned randomized, blinded, placebo-controlled Phase 3 will enroll ~120 patients across up to 50 centers, treat patients up to 14 days on background anticoagulant therapy, use centrally adjudicated incidence of new or worsening thrombotic events in SRA-confirmed HIT as the primary endpoint, include at least one interim analysis, and targets an NDA submission in 2029. Phase 2 showed >25% absolute reduction in thrombotic events when CAD-1005 was added to standard anticoagulant therapy.